An FDA advisory committee voted against allowing a sleep peptide to be compounded, citing safety and efficacy concerns during a two-day meeting to discuss whether seven peptides popular in wellness circles should be permitted.
The committee examined the peptides as part of a broader review of which compounds pharmacists are allowed to create in their facilities under current federal regulations.
